|
|
|
|
Turning a poorly soluble molecule into a viable oral product starts with the right formulation. Lonza experts walk through how they develop a spray-dried powder formulation and scale it from early feasibility to commercial manufacturing.
|
|
|
|
|
What’s new in pharmaceutical spray drying? Lonza experts share recent process enhancements and new approaches for converting molecules poorly soluble in both aqueous and organic solvents into amorphous dispersions for better oral bioavailability.
|
|
|
|
|
Oligonucleotide payloads aren’t small molecules, and standard ADC playbooks don’t fully apply. Their size, charge, and analytical challenges force changes to conjugation optimization, OAR quantification, chromatography selection, and TFF strategy.
|
|
|
|
|
Scaling spray-dried dispersions puts bioavailability, yield, and physical stability at risk. This white paper outlines a material-sparing, model-based approach to identify process sensitivities before late-stage development, with a case study on a challenging molecule.
|
|
|
|
|
|
|
Demand is growing for a seamless path from clinical development to commercial manufacturing. Iwan Bertholjotti, Lonza’s Senior Director of Commercial Development for Bioconjugates, explains how Lonza is expanding its bioconjugate capabilities to meet it.
|
|
|
